Magnitude and Complexity of Rectal Mucosa HIV-1-Specific CD8+ T-Cell Responses during Chronic Infection Reflect Clinical Status

J. William Critchfield1, Delandy H. Young1, Timothy L. Hayes1, Jerome V. Braun2, Juan C. Garcia3, Richard B. Pollard4, Barbara L. Shacklett1,4*

1 Department of Medical Microbiology and Immunology, University of California Davis, Davis, California, United States of America, 2 Department of Statistics, University of California Davis, Davis, California, United States of America, 3 Department of Medicine, Division of Gastroenterology, School of Medicine, University of California Davis, Sacramento, California, United States of America, 4 Department of Medicine, Division of Infectious Diseases, School of Medicine, University of California Davis, Sacramento, California, United States of America

Abstract

Background: The intestinal mucosa displays robust virus replication and pronounced CD4+ T-cell loss during acute human immunodeficiency virus type 1 (HIV-1) infection. The ability of HIV-specific CD8+ T-cells to modulate disease course has prompted intensive study, yet the significance of virus-specific CD8+ T-cells in mucosal sites remains unclear.

Methods and Findings: We evaluated five distinct effector functions of HIV gag-specific CD8+ T-cells in rectal mucosa and blood, individually and in combination, in relationship to clinical status and antiretroviral therapy (ART). In subjects not on ART, the percentage of rectal Gag-specific CD8+ T-cells capable of 3, 4 or 5 simultaneous effector functions was significantly related to blood CD4 count and inversely related to plasma viral load (PVL) (p<0.05). Polyfunctional rectal Gag-specific CD8+ T-cells expressed higher levels of MIP-1β and CD107a on a per cell basis than mono- or bifunctional cells. The production of TNFα, IFN-γ, and CD107a by Gag-specific rectal CD8+ T-cells each correlated inversely (p<0.05) with PVL, and MIP-1β expression revealed a similar trend. CD107a and IFN-γ production were positively related to blood CD4 count (p<0.05), with MIP-1β showing a similar trend. IL-2 production by rectal CD8+ T-cells was highly variable and generally low, and showed no relationship to viral load or blood CD4 count.

Conclusions: The polyfunctionality of rectal Gag-specific CD8+ T-cells appears to be related to blood CD4 count and inversely related to PVL. The extent to which these associations reflect causality remains to be determined; nevertheless, our data suggest a potentially important role for mucosal T-cells in limiting virus replication during chronic infection.

Citation: Critchfield JW, Young DH, Hayes TL, Braun JV, Garcia JC, et al. (2008) Magnitude and Complexity of Rectal Mucosa HIV-1-Specific CD8+ T-Cell Responses during Chronic Infection Reflect Clinical Status. PLoS ONE 3(10): e3577. doi:10.1371/journal.pone.0003577

Editor: Douglas F. Nixon, University of California San Francisco, United States of America

Received August 18, 2008; Accepted October 7, 2008; Published October 30, 2008

Copyright: © 2008 Critchfield et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by grants from the National Institutes of Health (NIH-NIAID R01 AI057020) and the California HIV/AIDS Research Program (CH05-D-606). This investigation was conducted in a facility constructed with support from Research Facilities Improvement Program Grant Number C06 RR-12088-01 from the National Center for Research Resources, National Institutes of Health. The LSR-II violet laser was upgraded with funding from the James B. Pendleton Charitable Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: blshacklett@ucdavis.edu

Introduction

A significant body of work has demonstrated the contribution of HIV-specific CD8+ T-cell responses to immunological control of HIV infection [1–3]. However, the relationship between cytotoxic T-lymphocyte (CTL) response magnitude and clinical parameters has proven controversial. Mathematical models based upon the ability of CTL to clear virally infected cells predicted an inverse relationship between blood CTL frequency and HIV plasma viral load in the absence of antiretroviral therapy [4]. Some reports, using MHC class I tetramers and/or Elispot assays to quantify HIV-specific T-cell responses, did in fact reveal such an inverse relationship [5,6]. However, subsequent studies did not produce a consensus on this point: one study reported a positive correlation between plasma viral load and the total HIV-specific, Env-, and Nef-specific CD8+ T-cell frequency [7], while at least two others found no numerical relationship [8,9]. Recently, additional light has been shed on this issue by reports documenting a unique relationship between the breadth and/or magnitude of Gag-specific CD8+ T-cell responses (but not Env, Pol or Nef-specific responses) and plasma viremia and/or blood CD4 count [10–16]. Mechanisms proposed to explain the immunodominance of Gag-specific responses include early recognition of infected cells by Gag-specific CTL [17] and immune pressures exerted by CTL specific for conserved Gag functional domains [18].

Given the ambiguous relationship between HIV-specific T-cell response magnitude and clinical parameters, investigators have sought new combinations of immunological markers whose expression might more reproducibly correlate with clinical status. The advent of multiparameter flow cytometry, allowing the simultaneous measurement of multiple effector molecules, has led to an emphasis on T-cell response “quality” or “functional
heterogeneity” rather than “quantity” or “magnitude” of IFNγ responses alone [19]. While it could be argued that the measurement of five functions will not necessarily provide more relevant information than the measurement of a single function, recent findings have in fact demonstrated the added value of this approach. HIV long-term nonprogressor status was associated with the ability of HIV-specific CD4+ T-cells to produce both IL-2 and IFNγ [20]. Conversely, in individuals with progressive disease, HIV-specific CD4+ T-cell responses were skewed towards production of IFNγ in the absence of IL-2 [21]. In one study, the ability to mount 4 and 5 functions simultaneously (i.e., IFNγ, TNFα, IL-2, MIP-1β and CD107α) was a characteristic of HIV-specific CD8+ T-cells in long-term nonprogressors [22]. In a related study, the control of HIV-1 replication in HLA-B27 subjects was associated with the ability of B27-KK10-specific CD8+ T-cells to mount multiple effector functions [23]. T-cell responses associated with successful vaccines also support the clinical relevance of polyfunctionality. Humans immunized with vaccinia virus generate polyfunctional virus-specific CD8+ T-cells [24], and vaccine-induced protection of mice challenged with *Leishmania major* is accompanied by T-helper type 1 cells that are able to produce multiple cytokines [25].

Most prior studies of HIV-specific cell-mediated immunity have assessed responses only in the peripheral blood compartment; little information is available concerning HIV-specific T-cell responses in mucosal tissues. In a previous study focused primarily on IFN-γ production, we reported that rectal CD8+ T-cell responses to Gag were immunodominant (as compared to Pol and Env) in chronically infected subjects not on antiretroviral therapy with a broad range of viral loads [26]. We also found that the production of IFN-γ by rectal HIV-gag CD8+ T-cells was positively associated with blood CD4 count during chronic infection [26], and began to explore the ability of rectal CD8+ T-cells to mount multiple effector responses, including CD107α, TNF-α and IFN-γ. In the present study, we have extended these analyses to include five effector functions, both individually and combination, building upon our existing cohort of individuals with chronic HIV infection.

In the present work, we have analyzed paired blood and rectal biopsies from chronically infected patients for five distinct responses to HIVgag stimulation: production of the cytokines IFN-γ, IL-2, TNF-α, the chemokine MIP-1β, and the cytolytic granule constituent CD107α, which is an indirect marker for cytotoxic potential [27]. We present a detailed analysis of the relationship between each individual effector function and clinical parameters, as well as the relationship between T-cell polyfunctionality and clinical parameters. The patient group includes 15 individuals not on antiretroviral therapy (ART) with viral loads ranging from <50 to >50,000 copies/ml, as well as 13 patients on ART for at least one year. We also introduce a new statistics-based approach to determining when an antigen-specific response is significantly different from background; the aim of this tool is to remove potential bias and facilitate data interpretation in instances when cell number is variable and background high, as is frequently the case with mucosal samples.

Using an expanded panel of response parameters coupled with a new and rigorous statistical approach to evaluating when a response is significant (see Materials & Methods), here we report on multiple significant associations between CD8+ T-cell responses in rectal mucosa and both plasma viral load and blood CD4 count. Such associations were not evident when evaluating peripheral blood CD8 responses in relationship to plasma viral load or blood CD4 count in the same patients. We also report that HIV-specific CD8+ T-cell responses in rectal mucosa of patients on long-term suppressive ART are characterized by low magnitude and a marked qualitative shift towards monofunctional responses when compared to patients not on ART. Thus, rectal mucosal CD8+ T-cells are not only capable of potent and diversified effector responses, but these responses bear a relationship to clinical status during chronic HIV infection.

### Results

#### Characteristics of Study Subjects

Plasma viral load, blood CD4 count, and other clinical information for the 36 study participants are shown in Table 1. Study participants included 15 seropositive individuals not on ART, 13 seropositive subjects on ART, and 8 seronegative volunteers. Several of these patients participated in an earlier study of mucosal T-cell responses [26]; however, fresh biopsy samples were obtained for the present work. For seropositive subjects, the number of years since initial HIV-1 seropositivity ranged from 1 to 25 years. Time since seroconversion averaged 8.3 years for patients not on ART and 10.7 years for patients on ART, a difference which was not statistically significant (Mann Whitney test, 2-tailed, p>0.05). The subject pool was primarily Caucasian (56%) and African American (33%), and the gender distribution was approximately two-thirds male and one-third female. Among seropositive subjects not on ART, viral loads ranged from <50 to 89,700 copies per ml plasma, and blood CD4 counts ranged from 304 to 883 cells per μl blood (Table 1). Among the 13 subjects on ART, the time since ART initiation ranged from 1–15 years; drug combinations at the time of biopsy are given in Table 1. Three of the 13 subjects on ART did not have fully suppressed plasma viremia. Seronegative subjects were confirmed to be uninfected by HIV-1 antibody testing and plasma viral load testing.

#### Flow cytometry gating

The gating strategy used to analyze data from the ICS assay of a typical rectal MNC sample stimulated with HIVgag peptides plus costimulatory antibodies is illustrated in Figure 1. A lymphocyte gate based on forward/side scatter was followed by a viability gate (7-AAD negative) and selection of cells positive for both CD3 and CD8. These cells were further subdivided into individual populations consisting of cells positive for MIP-1β, IFN-γ TNF-α, IL-2, and CD107α. Values from these populations were either analyzed directly or the populations further subdivided into 31 possible combinations of functions [22,28]. In either case, values were background-corrected as described in Materials and Methods, using values from cells treated with costimulatory antibodies alone. For phenotyping of rectal and peripheral CD8+ T-cells, unstimulated cells underwent the same gating strategy except that the CD3+CD8+ population was further divided based upon expression of phenotypic markers rather than response markers.

#### Rectal CD4+ T-cell percentages reflect peripheral blood CD4 percentages in the group on ART

The dynamics of CD4+ T-cell restoration in mucosal tissues following initiation of ART is an area of current interest [29,30]. We therefore measured CD4+ T-cells as a percentage of CD3+ T-cells and explored the relationship between CD4+ T-cell frequencies in rectal mucosa and blood in a cross-sectional analysis of subjects either on or off ART, as shown in Fig. 2. CD4+ T-cell levels in both rectal mucosa and PBMC were lower in HIV-infected individuals, irrespective of ART status, compared to seronegative controls (Fig 2A). Although rectal CD4+ T-cell percentages were frequently lower than blood CD4+ T-cell percentages in patients not on ART, a comparison of CD4+ T-
cell percentages between rectal mucosa and PBMC in both patient groups, using paired T-tests, did not reveal significant differences between tissues. Of note, the group on ART had a higher median rectal CD4<sup>+</sup> T-cell frequency (39.6%) compared to the group not on ART (28.0%), though this difference was not statistically significant. Moreover, the group on ART displayed a significant positive correlation between rectal and peripheral CD4 percentages (Fig. 2B, p = 0.001), while the group not on ART failed to show such a relationship (Fig. 2C). The group on ART also displayed an inverse correlation (p<0.05) between rectal CD4 percentage and plasma viral load (data not shown).

Rectal CD8<sup>+</sup> responses are robust compared to PBMC, but are strongly attenuated by ART

All Gag-specific responses reported in this study were first evaluated for significance, in relation to responses associated with exposure to costimulatory antibodies alone, using a statistical test.

| Patient ID<sup>a</sup> | Gender<sup>b</sup> | Ethnicity<sup>c</sup> | HLA Class I Genotype | Blood CD4 (cells/mm<sup>3</sup>) | Plasma VL (RNA copies/ml) | Yrs HIV<sup>d</sup> | ART (at time of biopsy)<sup>e</sup> | ART Duration (minimum time) |
|------------------------|-------------------|---------------------|----------------------|-------------------------------|------------------------|----------|-------------------------------|---------------------------|
| 6                      | M                 | AA                  | A2/A74/B49/B81       | 367                           | 1,130                  | 17       | No                            | NA                        |
| 14                     | F                 | H                   | A3/A11/B7/B27        | 740                           | 5,370                  | 11       | No                            | NA                        |
| 28                     | F                 | AA                  | A30/B8/B27           | 619                           | 281                    | 18       | No                            | NA                        |
| 39                     | M                 | C                   | A1/A29/B8/B44        | 304                           | 76,000                 | 3        | No                            | NA                        |
| 41                     | M                 | C                   | A1/A2/B51/B58        | 538                           | 89,700                 | 7        | No                            | NA                        |
| 42                     | M                 | C                   | A2/A3/B14/B39        | 669                           | 703                    | 25       | No                            | NA                        |
| 43                     | F                 | C                   | A1/A2/B37/B57        | 571                           | 12,700                 | 5        | No                            | NA                        |
| 44                     | M                 | C                   | A1/A2/B7/B8          | 719                           | 63,800                 | 1        | No                            | NA                        |
| 45                     | M                 | C                   | A23/A68/B8/B51       | 481                           | 83,900                 | 1        | No                            | NA                        |
| 46                     | M                 | C                   | A11/A24/B13/B52      | 715                           | 27,100                 | 1        | No                            | NA                        |
| 47                     | M                 | H                   | A11/A31/B15/B51      | 463                           | 34,900                 | 9        | No                            | NA                        |
| 48                     | M                 | H                   | A2/A68/B18/B57       | 636                           | 109                    | 1        | No                            | NA                        |
| 49                     | F                 | C                   | A2/A30/B14/B52       | 553                           | 7,170                  | 11       | No                            | NA                        |
| 50                     | M                 | C                   | A1/A68/B27/B57       | 883                           | <50                    | 10       | No                            | NA                        |
| 51                     | F                 | AA                  | A30/A68/B45          | 358                           | 11,000                 | 12       | FTC+TDF+EFV                   | 10 yr                     |
| 52                     | T                 | C                   | A24/A68/B51          | 512                           | <50                    | 17       | Efavirenz+3TC+TDF             | 1 yr                      |
| 53                     | M                 | C                   | A1/B7/B8             | 442                           | <50                    | 7        | AZT+3TC+EFV                   | 4 yr                      |
| 54                     | F                 | C                   | A1/A2/B8/B44         | 464                           | <50                    | 4        | TDF+EFV+ABC+AZT               | 4 yr                      |
| 55                     | M                 | C                   | A11/A24/B7/B44       | 851                           | <50                    | 24       | ABC+3TC+ATV+RTV              | 15 yr                     |
| 56                     | M                 | AA                  | A2/A33/B53/B57       | 408                           | <50                    | 17       | FTC+TDF+RTV+ATV              | 3 yr                      |
| 57                     | M                 | C                   | A2/A31/B44/B51       | 927                           | <50                    | 17       | FTC+TDF+RTV+ATV              | 3 yr                      |
| 58                     | M                 | AA                  | A68/B7/B58           | 527                           | 557                    | 6        | DDI+TDF+RTV+FPV              | 4 yr                      |
| 59                     | M                 | AA                  | A23/A74/B15/B18      | 287                           | <50                    | 1        | DDI+TDF+LPV+RTV              | 2 yr                      |
| 60                     | M                 | C                   | A2/A29/B14/B49       | 316                           | <50                    | 6        | AZT+3TC+EFV                  | 4 yr                      |
| 61                     | I                 | A                   | A3/B7/B49            | 434                           | 7,660                  | 6        | ABC+3TC+ATV                  | 2 yr                      |
| 62                     | M                 | C                   | A2/A26/B40/B44       | 545                           | <50                    | 19       | FTC+TDF+LPV+RTV              | 6 yr                      |
| 63                     | F                 | C                   | A1/B8/B39            | 809                           | <50                    | 3        | 3TC+TDF+RTV+ATV              | 3 yr                      |
| 64                     | M                 | AA                  | A23/A24/B15/B27      | 837                           | <50                    | NA       | HIV neg                      | NA                        |
| 65                     | M                 | AA                  | A30/A68/B15/B57      | 322                           | <50                    | NA       | HIV neg                      | NA                        |
| 66                     | F                 | AA                  | A23/B18/B49          | 670                           | <50                    | NA       | HIV neg                      | NA                        |
| 67                     | F                 | C                   | A2/A24/B7/B57        | 742                           | <50                    | NA       | HIV neg                      | NA                        |
| 68                     | F                 | C                   | A2/B8/B35            | 714                           | <50                    | NA       | HIV neg                      | NA                        |
| 69                     | F                 | As                  | A11/A33/B44/S1       | 228                           | <50                    | NA       | HIV neg                      | NA                        |
| 70                     | M                 | AA                  | ND                  | 1396                          | <50                    | NA       | HIV neg                      | NA                        |
| 71                     | M                 | AA                  | A30/A4/B4/B49        | 609                           | <50                    | NA       | HIV neg                      | NA                        |

<sup>a</sup>ID, identification number.
<sup>b</sup>M, male; F, female; T, transgender; I, intersex.
<sup>c</sup>AA, African-American; As, Asian; C, Caucasian; H, Hispanic.
<sup>d</sup>ABC, Abacavir; ATV, Atazanavir; AZT, Azidothymidine; DDI, Didanosine; EFZ, Efavirenz; FPV, Fosamprenavir; FTC, Emtricitabine; LPV, Lopinavir; RTV, Ritonavir; TDF, Tenofovir Disoproxil Fumarate; 3TC, Lamivudine.

doi:10.1371/journal.pone.0003577.t001
rather than a simple cutoff value (see Materials & Methods). Responses to HIVgag peptide stimulation (i.e., percentages of responding CD8+ T-cells) were first analyzed individually, as summarized in Figure 3. For CD107a, IFN-γ, MIP-1β, and TNF-α, responses were vigorous in both tissue compartments in patients not on ART. IL-2 production by CD8+ T-cells was weak or absent in most subjects and in both tissues. In the subject group not on ART, rectal responses were particularly robust compared to blood; for CD107a and IFN-γ the differences between median response magnitudes when comparing rectal mucosa to blood were greater than 2-fold and were statistically significant. As predicted, mucosal T-cell responses in patients on ART were lower in magnitude than in the untreated group. Furthermore, the difference in response magnitude in rectal mucosa between patients off and on ART was statistically significant for three functions: CD107a, IFN-γ, and MIP-1β (Figure 3). Although response magnitudes in PBMC showed a similar trend, only one function, MIP-1β production, showed a significant difference when comparing the two treatment groups. Thus, ART was associated with a particularly striking decrease in the magnitude of HIV-specific T-cell effector functions in rectal mucosa.

Rectal but not peripheral CD8+ T-cell response magnitudes in subjects not on ART correlate with plasma viral load and blood CD4 count

As shown in Fig. 3, the group of subjects not on ART displayed a broad range of response magnitudes in both rectal mucosa and blood for each individual function, with the exception of IL-2. For example, net rectal CD107a response values ranged from zero to 10.4%. To investigate whether response magnitudes were related to virus replication or clinical status, we looked for correlations to virus replication or clinical status, we looked for correlations.
2), the predominant 3+ group (lacking IL-2 and TNF-α), the predominant 2+ group (expressing only CD107a and MIP-1β), and the predominant 1+ group expressing only MIP-1β.

The mean total percentage of rectal CD8+ T-cells responding to HIV gag stimulation in any way (i.e., all 31 non-overlapping categories combined) was 5.9% for the group not on ART. The pie charts and bar graphs provide finer details illustrating that nearly one-half of the rectal response in patients not on ART was comprised of polyfunctional cells capable of 3, 4, or 5 responses simultaneously. In contrast, in the group on ART, the mean percentage of rectal CD8+ T-cells responding to HIV gag stimulation was 2.9%. Even more strikingly, cells producing 3, 4, or 5 responses accounted for less than 10% of the responding population, as shown in the pie chart. Thus, in this cross-sectional comparison of patients on and off ART, ART was associated with a striking absence of polyfunctionality in rectal mucosa.

In PBMC of patients not on ART, the mean percentage of HIV gag-specific CD8+ T-cells was lower than in rectal mucosa (3.8% vs. 5.9%), and approximately 30% of this response was derived from cells capable of at least 3 responses. In the ART group, the mean percentage of responding cells was 1.1%, fewer than 20% of which were polyfunctional. Figure 5B is a graphical representation of the results of linear mixed model analysis for the data shown in Figure 5A. Data for each tissue and patient group are summarized by individual bars, and letter codes are used to identify statistically significant differences between groups. Polyfunctional cells, capable of 3, 4 or 5 functions, are represented by open bars, and cells capable of only 1 or 2 functions are represented by filled bars. As shown in the figure, HIV gag-specific responses in patients on ART showed reduced magnitude and complexity as compared to responses in patients not on ART. Notably, CD8+ T-cell response complexity was far more sensitive to ART in rectal mucosa than in PBMC in this cross-sectional data set.

Response complexity is related to blood CD4 count and plasma viral load

The utility of Boolean gating analysis lies not only in the ability to assemble a detailed view of responding CD8+ T-cell populations (Fig. 5), but also in the opportunity to look within selected response categories for relationships between responses and clinical status. We therefore asked whether any single response category in blood or rectal mucosa, or combination of categories, was significantly related to blood CD4 count or plasma VL. These analyses were limited to those T-cell response categories for which at least 50% of the responses were greater than zero, and the analysis of subjects was limited to those not on ART, since those on ART had a high percentage of zero values.

Rectal, but not peripheral, Gag-specific CD8+ T-cell responses within certain functional categories showed significant correlations with clinical status. The strongest of these relationships was observed when the percent response was summed across the three predominant polyfunctional categories and the summed values were plotted against blood CD4 count or plasma viral load. Figure 6 shows results of this analysis; the total of 3+, 4+ and 5+ CD8+ T-cell frequencies was positively correlated with blood CD4 count (r = 0.621, p = .024) and negatively correlated with plasma viral load (r = -0.636, p = .026). In contrast, the summed 1- and 2-function responses showed no relationship to blood CD4 or plasma viral load (not shown). Additional significant correlations (p <.05) included mucosal 4- and 3-function CD8 responses in relation to blood CD4 count; mucosal 4-function CD8 responses in relation to plasma viral load; and the summed 1+ through 5+ mucosal Gag-specific CD8 response in relation to blood CD4 count and plasma viral load (data not shown). Although similar
statistical analyses were performed for blood CD8+ T-cell responses, we did not identify any significant relationships between total blood CD8 responses or any subset of blood CD8 responses and either plasma VL or blood CD4 count (not shown). In addition, functionality of rectal CD8+ T-cell responses failed to exhibit any significant correlation with rectal CD4 frequency as a percent of CD3+ T-cells (not shown).

The production of MIP-1β and CD107a on a per-cell basis intensifies as cell functionality increases

Polyfunctional CD8+ T-cells have previously been demonstrated to produce more IFN-γ on a per-cell basis than cells of lower functionality [23–25]. In the present data set, the expression of MIP-1β and CD107a were highly conserved across the predominant response categories for subjects on ART (Fig. 5). This pattern of conserved expression afforded the opportunity to evaluate the median fluorescence intensity (MFI) of these factors across the spectrum from single-positive to 5-function positive cells in both PBMC and rectal mucosa. MFI values were adjusted by subtracting the MFI of cells negative for expression. As shown in Figure 7, MIP-1β and CD107a MFIs in rectal CD8+ T-cells (Figs. 7A & 7B) were significantly increased at higher levels of response complexity compared to single positive cells. In peripheral blood (Figs. 7C & 7D), MIP-1β showed the same pattern as in rectal mucosa, while CD107a MFI showed no changes across the response categories.

The expression of activation markers and perforin and granzyme on CD8+ T-cells reveals tissue and ART-dependent effects

Typical lymphocyte activation markers were generally expressed at higher levels by CD8+ T-cells in rectum than in PBMC (Fig. 8). In agreement with earlier studies [31], the early activation marker CD69 was highly expressed on rectal CD8+ T-cells as compared to PBMC. This high level of expression, approximately 75%, was unaffected by ART and was equally high in the seronegative group. The expression of CD25 was lower in magnitude but similar in expression pattern to that of CD69; this marker was more highly expressed in rectal CD8+ T-cells generally than in PBMC, irrespective of ART or serological status. The activation marker HLA-DR was more strongly expressed in rectal mucosa than PBMC of all three groups, and showed a trend towards higher expression in rectal mucosa of seropositive patients not on ART as compared to other groups.

As previously reported, perforin expression was extremely low in rectal CD8+ T-cells as compared to PBMC [32]; however, three untreated HIV positive patients in this study expressed perforin in >20% of rectal CD8+ T-cells. Granzyme B expression in rectal mucosa CD8+ T-cells of seropositive individuals not on therapy was significantly elevated compared to both subjects on ART and seronegative subjects. This pattern was also evident in PBMC, though in this compartment the effect of ART was not statistically significant.

Discussion

In this study we introduce the use of a statistical approach to establish when an antigen-specific response is significantly different from the response elicited by costimulatory antibodies alone (see Materials & Methods). While this issue may seem mundane, it is in fact critically important when small populations of responding cells are distributed amongst 31 Boolean combinations, a process that can result in categories containing relatively few events (i.e., individual cells), as is frequently the case for samples derived from tissue biopsies [33]. Further, baseline cytokine production in rectal mucosa is generally higher than in PBMC [26,34,35]; this higher background is another reason to apply greater rigor in determining the significance of antigen-specific responses. The method we present here takes into account the absolute numbers of responding cells in a given sample, as well as the total number of cells analyzed. This permits a statistical evaluation on a category-by-category basis of whether an antigen-specific response is significantly different from background. Accordingly, this approach may prove useful for future studies of mucosal immune responses, including for vaccine trials.

Virions in circulation are thought to originate from tissue sites of active virus replication. As the intestinal tract is a major lymphoid organ that supports high levels of virus replication during acute infection, it may also serve as a significant source of viremia during chronic infection. In a previous study of a more limited patient group, we observed that plasma viremia was inversely, though not significantly, associated with IFNγ production by Gag-specific rectal CD8+ T-cells, while blood CD4 count showed a significant positive correlation with Gag-specific rectal responses [26]. Here, by expanding our focus to include additional patients as well as five individual Gag-specific effector responses, we found that three (CD107a, IFNγ, and TNFα) of the five rectal responses were inversely correlated with plasma viral load (p<.05), and two (CD107a and IFNγ) were positively correlated with blood CD4
count (p<.05) (Fig 4) in patients not on ART. When evaluated in terms of polyfunctionality, as defined by the ability to mount 3, 4, or 5 responses simultaneously, significant relationships were also evident between rectal Gag-specific responses and both plasma viral load and blood CD4 count. Thus, our general finding is that greater responsiveness of rectal gag-specific CD8+ T-cells, but not peripheral blood CD8+ T-cells, is associated with lower plasma viral load and elevated blood CD4 count. Determination of whether the relationships between rectal antiviral responses and peripheral viral load are causal will require additional study. The degree to which rectal CD8 cells are responsible for limiting mucosal virus production remains unknown and awaits intensive analysis of tissue viral loads. It is also possible that mucosal CD8 responses are highest and most polyfunctional in individuals with low viremia due to a comparatively intact immune system and the availability of abundant CD4 help.

Others have observed that peripheral Gag-specific CD8+ T-cell responses have clinical relevance as suggested by high-magnitude
Figure 5. Detailed HIVgag response profile for CD8+ T-cells in rectal mucosa and blood. (A) Response profiles were generated using Boolean analysis of 5 functional response gates, resulting in 31 separate categories as described in the text. The percentage value shown in the center of each pie diagram denotes the total magnitude of CD8+ T-cells responding in any way (i.e., a summation across all 31 categories). Individual color-coded pie slices represent the fraction of cells within the total responding population displaying 5, 4, 3, 2, or 1 function(s), beginning at ‘12 o’clock’ and moving clock-wise, as compiled from the bar graph data. The bar graph provides fine detail on frequencies within each of the individual 31 categories; interquartile ranges and medians are shown. (B) Results from linear mixed model analysis of HIVgag-specific responses. ART status, tissue type, and polyfunctionality were treated as fixed effects (see Methods). Polyfunctional cells (open bars) were defined as cells positive for 3, 4, or 5 functions, and non-polyfunctional cells (closed bars) were defined as cells positive for 1 or 2 functions. Letters are statistical notations; bars that do not share a common letter are significantly different (p<0.05).

doi:10.1371/journal.pone.0003577.g005
Polyfunctionality was defined as the summed frequencies of the 5+ and predominant 4+ & 3+ groups (as shown in the bar graph, Fig. 4). This derived value was plotted (X-axis) against blood CD4 count or plasma viral load (Y-axis). Results for r and level of significance are shown. Comparable relationships between PBMC polyfunctional responses and clinical parameters are not shown, as they were not statistically significant.
doi:10.1371/journal.pone.0003577.g006

Figure 6. Correlation (Spearman) of polyfunctional rectal CD8+ T-cell responses and plasma viral load or blood CD4 count. Polyfunctionality was defined as the summed frequencies of the 5+ and predominant 4+ & 3+ groups (as shown in the bar graph, Fig. 4). This derived value was plotted (X-axis) against blood CD4 count or plasma viral load (Y-axis). Results for r and level of significance are shown. Comparable relationships between PBMC polyfunctional responses and clinical parameters are not shown, as they were not statistically significant.

and complex Gag-specific responses in HIV controllers [12,36], as well as the ability of Gag-specific CTL to target conserved epitopes in critical Gag functional domains, driving the introduction of CTL escape mutations [18,37]. In addition, several recent reports have revisited the relationship between peripheral Gag-specific CD8+ T-cell responses and clinical parameters in clade B and C-infected cohorts from North and South America as well as Africa [10–16]. Considering these findings and our own, there is emerging support for an association between peripheral and rectal mucosal CD4+ T-cell percentages, with values for both tissues being much more tightly clustered than in infected subjects.

In summary, we have shown here that rectal HIVgag-specific CD8+ T-cells from chronically infected subjects not on ART are able to mount robust and diverse effector responses which correlate positively with blood CD4 count and inversely with plasma viral load. These associations were not evident for peripheral blood CD8+ T-cells, suggesting a unique status for mucosal HIV-specific CD8+ T-cells which remains to be fully defined. In the context of ART, a predictable drop in the total responding CD8+ T-cells in both tissues was accompanied by a marked loss of response complexity in rectal mucosa. The provision of ART was also linked to the observation that peripheral and rectal mucosal CD4+ T-cell percentages, with values for both tissues being much more tightly clustered than in infected subjects.

Although a role for mucosal T-cell responses in limiting viral dissemination during early/acute infection has been postulated, the contribution of mucosal effector cells to the immune control of viral replication during chronic infection has not been addressed. The results presented here suggest that, when individuals throughout a broad range of viral loads and blood CD4 counts are evaluated, there are significant relationships between antiviral mucosal effector responses (both individually and in combination),
and both VL and CD4. However, a cause/effect relationship between mucosal CD8+ T-cells and clinical status cannot be definitively established due to the cross-sectional nature of this study; indeed, it is possible that polyfunctional responses are a consequence of an intact immune system in individuals with low viral replication, rather than the cause of low virus replication. Additional studies will be required to address the relationship between mucosal T-cell responses and tissue viral loads.

**Materials and Methods**

**Study participants, clinical procedures, and tissue processing**

Subjects were chronically HIV-infected patients and seronegative volunteers and at the Center for AIDS Research, Education and Services (CARES), Sacramento, CA. Patients taking and not taking antiretroviral drugs were enrolled in the study. This patient cohort has been described previously [26]; however, the tissue samples and the analytical results presented for this study are entirely new and have not been previously reported. Written informed consent for phlebotomy and rectal biopsy was obtained through study protocols approved by the Institutional Review Board, School of Medicine, University of California, Davis. Blood was collected by sterile venipuncture using EDTA as an anticoagulant. Twenty-four rectal biopsies were taken endoscopically approximately 10–15 cm from the anal verge as previously described [26]. Following isolation, PBMC and rectal mononuclear cells (RMC) were incubated overnight in complete medium [RPMI-1640 supplemented with fetal calf serum (15%), penicillin (100 U/ml), streptomycin (100 μg/ml), and glutamine (2 mM)]. Rectal cells were further treated with Piperacillin-Tazobactam (0.5 mg/ml) (Zosyn®, Wyeth Pharmaceuticals, Philadelphia, PA) to inhibit overgrowth of intestinal bacteria that may be present in rectal cell preparations.

**Flow cytometry, blood CD4 and plasma viral loads**

Flow cytometry data were acquired on an LSRII (BD Immunocytometry Systems, San Jose, CA) equipped with 405, 488, and 643 nm lasers and utilizing FACSDIVA software (BDI). Analysis of cytometry data was done with FlowJo software (Tree Star, Ashland, OR); for experiments measuring five functional responses, individual cytokine gates were evaluated alone and also processed through Boolean combinations to partition responding cells into one of 31 possible specific response categories. Cytometry data were biexponentially transformed in order to include all events. SPICE software (Mario Roederer, Vaccine Research Center, NIAID/NIH, Bethesda, MD) was used to graph response data.

Blood CD4 count was determined by the clinical laboratory at University of California, Davis, Medical Center. Plasma viral load was measured by the California Department of Health Services, Viral and Rickettsial Disease Laboratory using the Roche COBAS HIV-1 Monitor v1.5 test. This method has a sensitivity cutoff of 50 HIV-1 RNA copies per ml plasma.
Antibodies and viral peptides

Fluorochrome-labeled monoclonal antibodies to CD3 (clone UCHT1), CD107a (clone H4A3), IFNγ (clone B27), TNF-α (clone MAb11), IL-2 (clone 6344.111), MIP-1β (clone D21-1351), Granzyme B (clone GB11), and CD25 (clone M-A251) were purchased from Pharmingen (San Diego, CA), as were unlabeled CD28 (clone L293) and CD49d (clone L25), and 7-Amino-Actinomycin D (7-AAD). Fluorochrome-labeled anti-CD8 (clone 3B5), CD4 (clone S3.5), HLA-DR (clone TU36), and CD69 (clone CH/4) were purchased from Invitrogen. Anti-CD4 (clone SFCI12T4D11) was obtained from Beckman Coulter (Fullerton, CA) and anti-Human Perforin (clone PF-164) was obtained from MABTECH. The HIVgag peptide pool (p55, HXB2 sequence) consisted of 15-mers with an 11 amino acid overlap (BD Biosciences, San Jose, CA).

Intracellular cytokine staining (ICS), T-cell phenotyping, and Flow cytometry

ICS assays and phenotypic staining were carried out on freshly isolated PBMC and RMC that were rested overnight at 37°C, 5% CO2 prior to analysis. For ICS, cells were stimulated with pooled HIVgag peptides (3.5 μg/ml) plus costimulatory antibodies (CD28 and CD49d). Negative and positive controls were media containing peptide vehicle (DMSO) plus costimulatory antibodies, and staphylococcus enterotoxin B (SEB, 5 μg/ml), respectively. The expression of CD107a, MIP-1β, IL-2, TNF-α and IFN-γ were measured using a modification of a previously described method [26,27]. Briefly, 1×10^6 cells in 200 μl complete medium were treated with anti-CD28 (2.5 μg/ml), anti-CD49d (5 μg/ml), anti-CD107a, monensin (1 μM GolgiStopTM, BD Biosciences), brefeldin A (5 μg/ml, Sigma), and HIVgag peptide pool or DMSO. Following a 5 hour incubation, cells were incubated for 5 minutes in PBS/2% FCS/0.5 mM/EDTA, stained for surface markers and 7-AAD (Pharmingen) in PBS/2% FCS, then permeabilized using FACS Perm 2 (BD Biosciences). Cells were then washed in PBS/2% FCS, stained for intracellular markers and CD3, washed again, then stored at 4°C in PBS/1% formaldehyde until analysis (within 24 hours). Non-fluorescent Actinomycin D (2 μg/ml) was included in reagents after the 7-AAD staining step to saturate sites that could bind residual 7-AAD [41,42].

Phenotypic staining of unstimulated peripheral and rectal CD8+ T-cells for surface and intracellular antigens was carried out using Caltag Fix and Perm (Invitrogen) according to the manufacturer’s protocol. Stained cells were then washed in PBS/2% FCS, stained for intracellular markers and CD3, washed again, then stored at 4°C in PBS/1% formaldehyde until analysis (within 24 hours). Flow cytometry gating was as shown in Fig. 1, except that the endpoint gates were phenotypic markers rather than functional responses.
Determination of the statistical significance of net antigen-specific responses

Net antigen-specific responses were evaluated using a statistical test [43] to determine whether the percent of CD8+ T-cells responding to Gag plus costimulation differed significantly from the percent of CD8+ T-cells responding to costimulation alone. This step was considered critical to the analysis given the observation that mucosal lymphocytes are partially activated in vivo and frequently exhibit elevated cytokine production relative to PBMC [26,34,44,45]. The statistical test was based on the assumption of a Poisson distribution for both conditions, and calculations utilized the number of gated fluorescence events collected, rather than percentages. This was considered advantageous given the fact that mucosal cell isolation protocols generally yield a lower number of viable lymphocytes than PBMC isolation protocols [40]. Within this framework, a choice of tests was made that generally controls the significance level of the test to the nominal level [43]. The following formula shows how the statistical test was structured to accommodate flow cytometry response data:

\[ W_j = \frac{\ln(X_1/X_0) - \ln(n_1/n_0)}{1/X_0 + 1/X_1} \]

The value \( X_j \) is the number of cells (i.e., positive fluorescence events) responding to peptide plus costimulation within a total CD8+ T-cell population designated as \( n_j \). Similarly, \( X_0 \) is the number of events associated with costimulation alone within a total CD8+ T-cell population designated as \( n_0 \). The test was carried out as follows: (1) if one or both of \( X_0 \) and \( X_1 \) was equal to zero, then the value was set to 0.5; (2) the test statistic \( W_j \) was calculated; (3) the test statistic \( W_j \) was referred to a standard normal distribution and the \( \beta \)-value was calculated; (4) if the \( \beta \)-value was less than the significance level (0.05), this indicated that the background cytokine response and the Gag-stimulated cytokine response were statistically different. In this case, the background response was subtracted from the Gag-specific response to yield a statistically meaningful net response. If, on the other hand, the \( \beta \)-value was equal to or greater than 0.05, this indicated that the background cytokine response and the Gag-stimulated response were not statistically different. In this case, the net Gag-specific response was set to zero.

Statistical comparisons between tissues and between subjects

For comparisons of T-cell function between tissues within the same patients, paired T-tests (two-tailed) were used. Mann Whitney (two-tailed) tests were used to compare T-cell function data between subjects (i.e., on vs. off ART) within a given tissue type. Expression of phenotypic markers was compared between tissues within the same patients using a paired T-test, and between patient groups using a Kruskal-Wallis test followed by Dunn’s Multiple Comparison Test. Correlations between CD8+ T-cell response magnitudes and plasma viral load, CD4+ T-cell count (blood) and CD4+ T-cell frequency (rectal MNC) were determined using Spearman Correlation (GraphPad Prism, v3, Graph Pad Software, San Diego, CA). Linear regression analysis was used to display a best fit line to the data.

Linear mixed model analysis of cytokine responses

T-cell responses to antigenic stimulation were evaluated by Boolean partitioning of responses into 31 distinct responding populations [22,28]. For the purposes of linear mixed model analysis, we defined polyfunctional cells as those capable of 3, 4, or 5 responses, as distinct from mono- or dual-function cells. Percentage values were square root transformed for variance stabilization. The transformed data were analyzed using a linear mixed effect model with ART status, tissue type, and polyfunctionality as fixed effects (including all interactions), with a random effect for subject, and with unstructured correlation between the tissue and polyfunction measures within each subject. The model was estimated using restricted maximum likelihood, and degrees of freedom were calculated using the Kenward and Roger adjustment [46]. Post-hoc comparisons were performed using the Tukey-Kramer adjustment for multiple comparisons. The level of significance was set at 0.05. Model fit was assessed using graphical analysis of residuals and the Shapiro-Wilks test for normality. Analysis was implemented using the MIXED procedure in SAS for Windows, Version 9.1.

Acknowledgments

The authors thank Richard Donovan and colleagues at the California Department of Health Services, Richmond, CA, for plasma viral load analyses. We also thank Julie Elliott and Peter Anton, Mucosal Immunology Core Laboratory, University of California-Los Angeles AIDS Research Institute, for technical assistance and Megan Norris and Donna Lemongello, UC Davis, for performing HLA typing and blood processing. We acknowledge Mario Rodenher, NIH VRC, for providing the SPICE software program. We thank Drs. Paolo Troia and David Asmuth, and Ms. Melissa Schreiber, UC Davis Division of Infectious Diseases, for assistance with recruitment and scheduling. We are indebted to the study volunteers for their willingness to participate in this work.

Author Contributions

Conceived and designed the experiments: JW C JLH JCG. Analyzed the data: JW DHY TLJ JCG. Wrote the paper: JW BLS. Provided clinical expertise and patient referrals: RP.

References

1. Kouop RA, Saffir JT, Cao Y, Andrews CA, McLeod G, et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68: 4650–4655.
2. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, et al. (1999) Dramatic rise in plasma viremia after CD4+ T-cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189: 991–996.
3. Borrero P, Lesewski H, Wei X, Horwitz MS, Peffer N, et al. (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3: 205–211.
4. Wodarcz D, Hall SE, Usuku K, Ozanne M, Ogg GS, et al. (2001) Cytotoxic T-cell abundance and virus load in human immunodeficiency virus type 1 and human T-cell leukaemia virus type 1. Proc Biol Sci 268: 1215–1221.
5. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, et al. (1998) Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279: 2103–2106.
6. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, et al. (2002) Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 76: 2206–2212.
7. Berto MR, AmbrosecDr, Douek DC, Bonhoeffer S, Brenchley JM, et al. (2001) Analysis of total human immunodeficiency virus (HIV-specific CD4+ and CD8+ T-cell responses: relationship to viral load in untreated HIV infection. J Virol 75: 11903–11911.
8. Adlo MM, Yu NG, Rathod A, Cohen D, Eldridge RL, et al. (2003) Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1
10. Geldmacher C, Gray C, Nason M, Currier JR, Haule A, et al. (2007) A high viral burden predicts the loss of CD8 T-cell responses specific for dominant gag epitopes during chronic human immunodeficiency virus infection. J Virol 81: 13809–13815.

11. Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, et al. (2007) CD8 T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. J Virol 81: 5460–5471.

12. Kesperieja P, Ngumela K, Tholakagile C, Randuth D, Honeyborne I, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13: 46–51.

13. Novitsky VA, Gilbert PB, Shea K, McLane MF, Rybak NA, et al. (2006) Interactive association of proviral load and HIV-gamma-secretase T-cell responses in HIV-1-infected individuals. J Virol 80: 3122–3125.

14. Rolland M, Heckerman D, Deng W, Roussel CM, Coovadia H, et al. (2008) Broad and Gag-Biased HIV-1 Epitope Repertoires Are Associated with Lower Viral Loads. PLoS ONE 3: e1424.

15. Zuniga R, Laschetti A, Galvan P, Sanchez S, Sanchez C, et al. (2006) Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 80: 3667–3672.

16. Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, et al. (2007) Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 178: 2746–2754.

17. Leslie AJ, Pfaffertt KJ, Chetty P, Draenert R, Addo MM, et al. (2004) HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10: 292–293.

18. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and targeting of multiple gag-specific CD8+ T-cell epitopes. J Virol 81: 13809–13815.

19. Mehandru S, Polo MA, Temmer-Raez K, Jean-Pierre P, Manuelli V, et al. (2006) Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 3: e184.

20. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A (2002) Presence of virally infected cells in fixed cell preparations. Cytometry 14 (Suppl 6): 27.

21. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, et al. (2007) Superior control of HIV-1 replication by CD8+ T-cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204: 2473–2483.

22. Critchfield JW, Lemongello D, Walker DH, Garcia JC, Amsuth DM, et al. (2007) Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. J Virol 81: 5460–5471.

23. Novitsky VA, Gilbert PB, Shea K, McLane MF, Rybak NA, et al. (2006) Interactive association of proviral load and HIV-gamma-secretase T-cell responses in HIV-1-infected individuals. J Virol 80: 3122–3125.

24. Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, et al. (2003) Trafficking of human immunodeficiency virus type 1-specific CD8+ T-cells to gut-associated lymphoid tissue during chronic infection. J Virol 77: 5621–5631.

25. Shacklett BL, Cox CA, Quigley MF, Kreis C, Stollman NH, et al. (2004) Abundant expression of granzyme A, but not perforin, in granules of CD8+ T-cells in GALT: implications for immune control of HIV-1 infection. J Immunol 173: 641–648.

26. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A (2002) Presence of virally infected cells in fixed cell preparations. Cytometry 14 (Suppl 6): 27.

27.鎌田茂宏, 藤村真, 河村公也, 田中一郎, 木村幸之助, et al. (2003) Sensitive and viable detection of antigen-specific CD8+ T-cells by a flow cytometric assay for degranulation. J Immunol Methods 281: 65–78.

28. Lanorlax L, Roederer M, Kopf R (2006) Intracellular cytokine optimization and standard operating procedure. Nat Protoc 1: 1507–1516.

29. Guadalupé M, Sankaran S, George MD, Raye E, Verhoeven D, et al. (2006) Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 80: 6239–6242.

30. Novitsky VA, Polo MA, Temmer-Raez K, Jean-Pierre P, Manuelli V, et al. (2006) Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 3: e184.

31. Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, et al. (2003) Trafficking of human immunodeficiency virus type 1-specific CD8+ T-cells to gut-associated lymphoid tissue during chronic infection. J Virol 77: 5621–5631.

32. Shacklett BL, Cox CA, Quigley MF, Kreis C, Stollman NH, et al. (2004) Abundant expression of granzyme A, but not perforin, in granules of CD8+ T-cells in GALT: implications for immune control of HIV-1 infection. J Immunol 173: 641–648.

33. Roederer M (2008) How many events is enough? Are you positive? Cytometry A 73: 384–385.

34. McGowan I, Elliott J, Gorina G, Tanner K, Sibolshan C, et al. (2007) Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr 46: 417–425.

35. McGowan I, Elliott J, Fuerst M, Taing P, Boscardin J, et al. (2004) Increased HIV-1 mucosal replication is associated with generalized mucosal cytokine activation. J Acquir Immune Defic Syndr 37: 1228–1236.

36. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, et al. (2008) HLA Class I Restricted T-cell Responses May Contribute to the Control of HIV Infection, but Such Responses Are Not Always Necessary for Long-term Virus Control. J Virol 82: 282–289.

37. Martinez-Picado J, Prado JD, Fry EE, Pfaffertt K, Leslie A, et al. (2006) Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 80: 3617–3623.

38. Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, et al. (1999) Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 73: 797–800.

39. Lopez M, Soriano V, Callon N, Carellero A, Gonzalez-Lahoz J, et al. (2008) Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8+ T-cells. Eur J Immunol 38: 1548–1558.

40. Shacklett BL, Yang O, Hauser MA, Elliott J, Hubin L, et al. (2003) Optimization of methods to assess human mucosal T-cell responses to HIV infection. J Immunol Methods 279: 17–31.

41. Kenterhoff TJ, Holland SP, Wile JK (1993) Identification of non-viable cells in fixed cell preparations. Cytometry 14 (Suppl 6): 27.

42. Schmit I, Kraii WJ, Unterbaugarth CH, Braun J, Giorgi JV (1992) Dead cell discrimination with 7-aminactinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry 13: 204–208.

43. Ng HK, Tang ML (2005) Testing the equality of two Poisson means using the rate ratio. Stat Med 24: 955–965.

44. Wang HC, Zhou Q, Dragoo J, Klein JR (2002) Most murine CD8+ T lymphocytes to virus-specific CD4+ T-cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204: 1405–1416.